









Markets
/
Stocks
/
nasdaq-celu
/

Celularity Inc

CELU



View Detailed Chart

2.220USD

+0.030+1.37%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

54.63MMarket Cap

LossP/E TTM



Celularity Inc

2.220

+0.030+1.37%

Overview Company Financials Analysis

Analysis

Intraday

30m

Today

+1.37%

5 Days

-4.31%

1 Month

-38.50%

6 Months

+32.93%

Year to Date

+6.73%

1 Year

-19.57%

View Detailed Chart

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

89 / 175

Overall Ranking

267 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

6.000

Target Price

+173.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 201.64% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 54.22M.

Fairly Valued

The company’s latest PE is -0.84, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 15.80M shares, decreasing 8.17% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 500.13K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.90.